385
Participants
Start Date
May 11, 2005
Primary Completion Date
July 4, 2006
Study Completion Date
July 4, 2006
SB218352_15
Non-adjuvanted pandemic influenza A formulation 1 vaccine
SB218352_8
Non-adjuvanted pandemic influenza A formulation 2 vaccine
SB218352_4
Non-adjuvanted pandemic influenza A formulation 3 vaccine
SB218352_2
Non-adjuvanted pandemic influenza A formulation 4 vaccine
SB218352_8AL
Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
SB218352_4AL
Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
SB218352_2AL
Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
GSK Investigational Site, Ketzin
GSK Investigational Site, Tostedt
GSK Investigational Site, Bad Segeberg
GSK Investigational Site, Bad Bramstedt
GSK Investigational Site, Elmshorn
GSK Investigational Site, Finsterwalde
GSK Investigational Site, Dresden
GSK Investigational Site, Dresden
GSK Investigational Site, Geringswalde
GSK Investigational Site, Schmiedeberg
Lead Sponsor
GlaxoSmithKline
INDUSTRY